Endurance RP Eyes Lucrative Market with Senstend Launch

Endurance RP (HK:0575) has released an update.

Endurance RP’s commercial partner, Wanbang Biopharmaceutical, has submitted a New Drug Application for Senstend™ to China’s National Medical Products Administration, with approval anticipated by the end of 2025. The drug, aimed at treating premature ejaculation, targets a significant market of around 55 million men in China. Upon regulatory approval and first commercial sale, Endurance RP stands to receive substantial milestone payments, highlighting a lucrative opportunity for investors.

For further insights into HK:0575 stock, check out TipRanks’ Stock Analysis page.